These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23178313)

  • 1. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
    Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
    Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse.
    Braicu EI; Chekerov R; Richter R; Pop C; Nassir M; Loefgren H; Stamatian F; Muallem MZ; Hall C; Fotopoulou C; Sehouli J; Pietzner K
    Ann Surg Oncol; 2014 Mar; 21(3):955-62. PubMed ID: 24217786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
    Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
    Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.
    Angioli R; Capriglione S; Aloisi A; Ricciardi R; Scaletta G; Lopez S; Miranda A; Di Pinto A; Terranova C; Plotti F
    Ann Surg Oncol; 2015 Dec; 22(13):4217-23. PubMed ID: 25808099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.
    Polterauer S; Vergote I; Concin N; Braicu I; Chekerov R; Mahner S; Woelber L; Cadron I; Van Gorp T; Zeillinger R; Castillo-Tong DC; Sehouli J
    Int J Gynecol Cancer; 2012 Mar; 22(3):380-5. PubMed ID: 22266934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV.
    Ataseven B; Grimm C; Harter P; Heitz F; Traut A; Prader S; du Bois A
    Gynecol Oncol; 2016 Feb; 140(2):215-20. PubMed ID: 26691222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.